News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

OrthoMimetics Release: First Patient Treated With Implant For Regenerative Repair Of Articular Cartilage And Bone


3/6/2009 11:46:25 AM

Cambridge UK, 06 March 2009 Orthomimetics, the UK based regenerative medicine company, has enrolled the first patient in its European pilot clinical trial of Chondromimetic, the company's flagship product for the repair of articular cartilage and bone.

The single-centre study is being conducted under the supervision of world-renowned surgeon Professor Laszlo Hangody in Budapest, Hungary. The trial will evaluate the safety and efficacy of Chondromimetic using multiple outcome variables, and marks the beginning of Orthomimetics' comprehensive evidence-based clinical program to support the launch of Chondromimetic.

Chondromimetic is a resorbable medical device that supports the body's natural repair mechanisms to encourage the simultaneous repair of both articular cartilage and the bone to which it is attached. Chondromimetic harnesses Orthomimetics' proprietary materials technology that produces novel mechanical properties without the need for synthetic polymers or other additives that can produce adverse degradation products.

Commenting on the commencement of the trial, Andrew Lynn, CEO of Orthomimetics said: 'Surgeons today are rightly demanding a higher level of evidence to demonstrate the efficacy of products used to treat their patients. By working with respected surgeons such as Professor Hangody, Orthomimetics is committed to being a leader in providing sound clinical evidence to demonstrate the long-term benefit of our products.'

This first enrolment follows CE-mark approval for Chondromimetic, which enables the company to market the product in Europe.

Orthomimetics Limited is a medical technology company that specialises in the design, development, and manufacture of regenerative medical implants and minimally invasive delivery systems for the treatment of sports injuries, trauma and other conditions that affect knees, ankles and other articular joints. Formed in 2005 as the first spin-out venture from the Cambridge-MIT Institute, the company is bringing to market a line of medical device products designed to improve the treatment outcome of first-line surgical procedures for the regenerative repair of articular cartilage, meniscus, ligament and tendon injuries using natural biomaterials. These products are engineered to be compatible with existing surgical techniques and to work in combination with emerging cell- and biologics-based products.

For further information on Orthomimetics please go to our website: www.orthomimetics.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES